NEWPACE LTD

Their core work

NewPace is an Israeli medtech SME developing the Implantable Subcutaneous String Defibrillator (ISSD), a miniaturized cardiac rhythm management device designed to prevent sudden cardiac death. Their core work is the engineering and clinical validation of an implantable defibrillator that uses a subcutaneous string-form factor — a departure from traditional bulky transvenous devices. They progressed through the full EU SME Instrument pipeline, completing a feasibility study before securing Phase 2 funding for the full device development and commercialization push. Their output is a market-ready medical hardware product aimed at patients who need defibrillation protection but are not candidates for conventional ICD implantation.

What they specialise in

How they've shifted over time

NewPace's H2020 activity is entirely concentrated on a single technology — the ISSD — with no discernible shift in research topic. What did evolve is their development maturity: the 2017 SME-1 project was a €50,000 feasibility study, while the 2018 SME-2 project received nearly €2.5M for full device development, clinical preparation, and market entry. This linear progression — from proof-of-concept to product — is the intended SME Instrument trajectory, and NewPace executed it successfully. There is no evidence of diversification into adjacent cardiac or digital health areas within the H2020 data available.

NewPace is on a commercialization trajectory with a single focused product; a future collaboration partner should expect a company deep in one specific device technology rather than a broad medtech research platform.

How they like to work

NewPace coordinated both of their H2020 projects as the sole beneficiary — a pattern typical of the SME Instrument, which is designed for single-company projects. There are no recorded consortium partners, meaning they have no traceable network of EU research collaborators from this data. Working with them would likely mean a bilateral engagement — either as a customer/partner for their device technology or as a clinical, regulatory, or manufacturing partner they bring in during commercialization.

Based on available H2020 data, NewPace has no recorded consortium partners and no cross-country collaborations through EU projects. Their engagement with the EU funding system was entirely through the solo-applicant SME Instrument track.

What sets them apart

NewPace is one of the few non-European (Israeli) SMEs to have completed the full SME Instrument Phase 1 → Phase 2 journey for an implantable cardiac device, which signals both technical credibility and EU regulatory awareness. Their ISSD addresses a specific clinical gap — patients who need defibrillation protection but cannot receive conventional transvenous ICDs — making them a niche player in a large, validated medical device market. For a consortium needing a cardiac device innovator or a clinical partner seeking a defibrillation technology provider, NewPace brings a near-market product rather than early-stage research.

Highlights from their portfolio

• ISSD (SME-2)
  Received €2,463,825 in Phase 2 SME Instrument funding — the full product development grant — making it one of the higher-value single-company H2020 medtech awards and confirming the technology passed EU expert feasibility review.
• ISSD (SME-1)
  The successful Phase 1 feasibility study that unlocked Phase 2 funding demonstrates that NewPace's subcutaneous defibrillator concept was validated by independent EU evaluators before full investment.